API reference
Decitabine
- CAS number
- 2353-33-5
- Molecular formula
- C8H12N4O4
- Molecular weight
- 228.21 g/mol
About this molecule
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment options, nucleoside analogues such as decitabine and [azacitidine] integrate into cellular DNA and inhibit the action of DNA methyltransferases, leading to global hypomethylation and related downstream therapeutic benefits. Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. It was first marketed under the name Dacogen®. It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine].
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
- InChIKey
- XAUDJQYHKZQPEU-KVQBGUIXSA-N
- SMILES
- C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O
- Other CAS numbers recorded
- 105597-46-4
- PubChem CID
- 451668
Also known as
Decitabine · 5-Aza-2'-deoxycytidine · 5-Azadeoxycytidine · 2'-Deoxy-5-azacytidine · 2-Desoxy-5-azacytidine · 5-Aza-deoxycytidine · Decitabina · 5-AZAdC
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.